ERBB2 and breast carcinoma: In addition, interactions with HER2 have been suggested, as cross-talk between IGF1R and HER2 has been implicated in resistance against trastuzumab, a monoclonal antibody used in breast cancer treatment to target HER2 receptors (46, 47).